BTVPUR AlSap 1
bluetongue-virus serotype-1 antigen
16
Medicinal product no longer authorised
authorised
Marketing authorisation holder: MERIAL
29 avenue Tony Garnier 69007 Lyon,
France
Manufacturer responsible for batch release: MERIAL
Laboratory of Lyon Porte des Alpes Rue de l’Aviation,
69800 Saint-Priest France
BTVPUR AlSap 1 suspension for injection for sheep and cattle
no
Each dose of 1 ml of vaccine (homogeneous milky white suspension) contains:
.Inactivated Bluetongue Virus Serotype 1...............................................................≥ 1.9 log10 pixels *
(*) Antigen content (VP2 protein) by immuno-assay
.Al3+ (as hydroxide) .................................................................................................................. 2.7 mg
.Saponin.................................................................................................................................. 30 HU**
Medicinal
(**)Haemolytic units
Active immunisation of sheep and cattle to prevent viraemia* and to reduce clinical signs caused by Bluetongue Virus Serotype 1.
*(below the level of detection by the validated RT-PCR method at 3.68 log10 RNA copies/ml, indicating no infectious virus transmission).
Onset of immunity has been demonstrated 3 weeks after the primary vaccination course. The duration of immunity for cattle and sheep is 1 year after the primary vaccination course.
None.
In very rare cases it has been observed a small local swelling at the injection site (at most 32 cm² in cattle and 24 cm² in sheep) which becomes residual 35 days later (≤ 1 cm2).
In very rare cases it has been observed a transient increase in body temperature, normally not
authorised
exceeding an average of 1.1 °C, may occur within 24 hours after vaccination.
The frequency of adverse reactions is defined using the following convention:
Very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment).
Common (more than 1 but less than 10 animals in 100 animals).
Uncommon (more than 1 but less than 10 animals in 1,000 animals).
Rare (more than 1 but less than 10 animals in 10,000 animals).
Very rare (less than 1 animal in 10,000 animals, including isolated reports).
If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.
Sheep and cattle.
no
Administer one dose of 1 ml subcutaneously according to the following vaccination scheme:
In sheep
1st injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune sheep).
2nd injection: after 3-4 weeks
In cattle
1st injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune cattle).
2nd injection: after 3-4 weeks.
Medicinal
Annual.
Apply usual aseptic procedures.
Shake gently immediately before use. Avoid bubble formation, as this can be irritating at the site of injection. The entire content of the bottle should be used immediately after broaching and during the
same procedure. Avoid multiple vial broaching.
Zero days.
authorised
Keep out of the sight and reach of children. Store and transport refrigerated (2 °C-8 °C).
Do not freeze.
Protect from light.
Shelf life after first opening the immediate packaging: immediately
Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP:
Special warnings for each target species:
If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals
prior to mass vaccination. The level of efficacy for other species may differ from that observed in sheep and cattle.
Special precautions for use in animals: Vaccinate healthy animals only.
Pregnancy and lactation:
Can be used during pregnancy in ewes. Can be used during pregnancy and lactation in cows
no
Fertility:
The safety and the efficacy of the vaccine have not been established in breeding males. In this category of animals the vaccine should be used only according to the benefit/risk assessment by the responsible veterinarian and/ or national Competent Authorities on the current vaccination policies against Bluetongue Virus (BTV).
Interaction with other medicinal products and other forms of interaction:
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary
medicinal product therefore needs to be decided on a case by case basis.
Medicinal
Overdose (symptoms, emergency procedures, antidotes):
Very rare and transient apathy can be observed after the administration of a double-dose of the vaccine. No other adverse reactions except those mentioned in section ‘Adverse Reactions’ were
observed.
Incompatibilities:
Do not mix with any other veterinary medicinal product.
Medicines should not be disposed of via wastewater or household waste.
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
authorised
Detailed information on this product is available on the website of the European Medicines Agency
The vaccine contains inactivated Bluetongue Virus Serotype 1 with aluminium hydroxide and saponin adjuvants. It induces an active and specific immunity against Bluetongue Virus Serotype 1 in the vaccinated animal.
Not all pack sizes may be marketed Box of 1 bottle of 10 doses (1 x 10 ml)
Box of 1 bottle of 50 doses (1 x 50 ml)
Box of 10 bottles of 50 doses (10 x 50 ml)
Box of 1 bottle of 100 doses (1 x 100 ml)
Box of 10 bottles of 100 doses (10 x 100 ml)
Medicinal
no
The manufacture, import, possession, sale, supply and/or use of BTVPUR AlSap 1 may be prohibited in a certain Member State on the whole or part of their territory pursuant to national legislation. Any person intending to manufacture, import, possess, sell, supply and/or use BTVPUR AlSap 1 must consult the relevant Member State’s competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use.